Pharmaceutical trade associations and drugmakers are preparing legal challenges to two proposed Medicare pricing demonstration models that would align U.S. prices with other wealthy nations, arguing the pilots exceed statutory authority and risk patient access. Industry filings and commentary outline constitutional and statutory claims and signal coordinated litigation readiness should CMS finalize the rules. Observers say the disputes could delay implementation and create regulatory uncertainty for pricing reform. STAT and other outlets chronicled the legal arguments and stakeholder submissions as the White House and HHS push high‑profile cost initiatives that pharma contends would undermine innovation incentives.